Vision

Pixium Vision provides clarification on Omnes Capital shareholding, unchanged since end 2017

Retrieved on: 
Friday, October 4, 2019
Ophthalmology, Vision, Senses, Emerging technologies, Macular degeneration, RTT, Senescence, Bionics, Retina, Photovoltaic retinal prosthesis, Maculopathy

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.

Key Points: 
  • Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy.
  • Pixium Visions bionic vision systems are associated with a surgical intervention and a rehabilitation period.
  • Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD).
  • The company is EN ISO 13485 certified and qualifies as Entreprise Innovante by Bpifrance.

Vision 2020 USA to Hold Annual World Sight Day Briefing on October 17, 2019

Retrieved on: 
Friday, October 4, 2019
Vision, World Sight Day

CHICAGO, Oct. 4, 2019 /PRNewswire-PRWeb/ --As part of World Sight Day events, on Thurs., Oct. 17, 2019, Vision 2020 USA will be holding an educational luncheon briefing at the Rayburn House Office Building, 2075 from noon to 1 p.m.

Key Points: 
  • CHICAGO, Oct. 4, 2019 /PRNewswire-PRWeb/ --As part of World Sight Day events, on Thurs., Oct. 17, 2019, Vision 2020 USA will be holding an educational luncheon briefing at the Rayburn House Office Building, 2075 from noon to 1 p.m.
  • Dr. Mitchell Brinks, MD, MPH, Chair of Vision 2020/USA will lead off the event with an update on Vision 2020 USA activities.
  • To attend the Vision 2020 USA World Sight Day briefing and luncheon, please contact Dina Beaumont at (202) 407-8325 or [email protected] .
  • VISION 2020 USA is committed to assuring the right to sight for all peoples both within the US and countries outside the US.

Clearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting

Retrieved on: 
Thursday, October 3, 2019
Visual system, Vision, Senses, Perception, Retina, Choroid, Macula of retina, Eye disease

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases.

Key Points: 
  • Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases.
  • Clearsides proprietary SCS Microinjector targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs.
  • These statements may be identified by words such as believe, expect, may, plan, potential, will, and similar expressions, and are based on Clearsides current beliefs and expectations.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Allergan to Showcase Late-Stage Data in Age-Related Macular Degeneration and Glaucoma at American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Thursday, October 3, 2019
Ophthalmology, Macular degeneration, RTT, Senescence, Macula of retina, Organ systems, Vision, Rinucumab

The Retina Subspecialty Day (October 11-12) will feature a late-breaker presentation on two-year data from the CEDAR and SEQUOIA clinical studies of Abicipar in patients with neovascular age-related macular degeneration (nAMD).

Key Points: 
  • The Retina Subspecialty Day (October 11-12) will feature a late-breaker presentation on two-year data from the CEDAR and SEQUOIA clinical studies of Abicipar in patients with neovascular age-related macular degeneration (nAMD).
  • Additional company-sponsored data will also be presented at the meeting as ePosters.
  • "We're excited to share data that may redefine treatment approaches in neovascular age-related macular degeneration and glaucoma, and may improve upon the current state of patient care."
  • Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

Visiongain Report Provides Critical Market-led Data on the $23bn Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market

Retrieved on: 
Thursday, October 3, 2019
Ophthalmology, Organ systems, Vision, Diabetes, Blindness, RTT, Diabetic retinopathy, Retinopathy, Retina, Macular degeneration

Dry AMD and Diabetic Retinopathy

Key Points: 
  • Dry AMD and Diabetic Retinopathy
    Key questions answered by this report:
    How is the retinal diseases market evolving and what are the market prospects from 2018?
  • How will revenues of retinal diseases segments grow over the forecast period, 2019 to 2029?
  • Which R&D pipeline products are likely to dominate the market in the next ten years, and what are their sales potentials?
  • How will market shares of top countries change by 2029 with their revenues and which regions will lead the market in 2029?

Visiongain Report Provides Critical Market-led Data on the $23bn Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market

Retrieved on: 
Thursday, October 3, 2019
Ophthalmology, Organ systems, Vision, Diabetes, Blindness, RTT, Diabetic retinopathy, Retinopathy, Retina, Macular degeneration

Dry AMD and Diabetic Retinopathy

Key Points: 
  • Dry AMD and Diabetic Retinopathy
    Key questions answered by this report:
    How is the retinal diseases market evolving and what are the market prospects from 2018?
  • How will revenues of retinal diseases segments grow over the forecast period, 2019 to 2029?
  • Which R&D pipeline products are likely to dominate the market in the next ten years, and what are their sales potentials?
  • How will market shares of top countries change by 2029 with their revenues and which regions will lead the market in 2029?

Camera, Lights, Action! GoPro Introduces HERO8 BLACK, Mods and MAX - Redefining What's Possible with a Camera

Retrieved on: 
Wednesday, October 2, 2019
3D imaging, Camcorders, GoPro, Omnidirectional camera, Vision, Imaging, Companies

HERO8 Black, the Mods and MAX totally redefine what's possible with a camera."

Key Points: 
  • HERO8 Black, the Mods and MAX totally redefine what's possible with a camera."
  • Waterproof (33' / 5m) and durable, HERO8 Black delivers everything you've come to expect from a flagship HERO camera, and more.
  • Use MAX as a waterproof (16' / 5m), maximum-stabilized single-lens HERO camera, dual-lens 360 camera or next-level vlogging camera with itsbuilt-infront-facing display and shotgun-mic audio capabilities.
  • GoPro users can submit their photos, raw clips and video edits to GoPro Awards for social stoke,GoProgear and cash prizes.

Blueprint Genetics, InformedDNA and the Foundation Fighting Blindness launch an open access program for patients with inherited retinal disease in the United States

Retrieved on: 
Wednesday, October 2, 2019
Ophthalmology, Vision, Organ systems, Foundation Fighting Blindness, Retina, Blindness, Rare diseases, Progressive retinal atrophy, Retinoschisis

The new program is an expansion of the My Retina Tracker genetic testing program established in 2017, when the Foundation Fighting Blindness partnered with Blueprint Genetics and InformedDNA to launch the My Retina Tracker genetic testing study.

Key Points: 
  • The new program is an expansion of the My Retina Tracker genetic testing program established in 2017, when the Foundation Fighting Blindness partnered with Blueprint Genetics and InformedDNA to launch the My Retina Tracker genetic testing study.
  • Now, My Retina Tracker will become available to all US patients with a clinical diagnosis of an inherited retinal disease (IRD).
  • The My Retina Tracker genetic testing program is expanding to be an open access, no-cost program for patients with a clinical diagnosis of an inherited retinal disease.
  • Established in 1971, the Foundation Fighting Blindness is the worlds leading private funding source for retinal degenerative disease research.

Myopia & Presbyopia Treatment Market Size Worth $28 Billion by 2026: Grand View Research, Inc.

Retrieved on: 
Wednesday, October 2, 2019
RTT, Vision, Near-sightedness, Presbyopia

SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- The global myopia and presbyopia treatment market size is expected to reach USD 28 billion by 2026, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- The global myopia and presbyopia treatment market size is expected to reach USD 28 billion by 2026, according to a new report by Grand View Research, Inc.
  • Growing prevalence of myopia and presbyopia is an opportunity for the market players to introduce efficient treatment solutions.
  • Factors such as introduction of technologically advanced surgical options and high adoption rate in the developed countries are expected boost growth of the myopia and presbyopia treatment market in the upcoming years.
  • Grand View Research has segmented the global myopia and presbyopia treatment market based on myopia treatment type, presbyopia treatment type, and region:
    Myopia Treatment Type Outlook (Revenue, USD Million, 2015 - 2026)

Myopia & Presbyopia Treatment Market Size Worth $28 Billion by 2026: Grand View Research, Inc.

Retrieved on: 
Wednesday, October 2, 2019
RTT, Vision, Near-sightedness, Presbyopia

SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- The global myopia and presbyopia treatment market size is expected to reach USD 28 billion by 2026, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- The global myopia and presbyopia treatment market size is expected to reach USD 28 billion by 2026, according to a new report by Grand View Research, Inc.
  • Growing prevalence of myopia and presbyopia is an opportunity for the market players to introduce efficient treatment solutions.
  • Factors such as introduction of technologically advanced surgical options and high adoption rate in the developed countries are expected boost growth of the myopia and presbyopia treatment market in the upcoming years.
  • Grand View Research has segmented the global myopia and presbyopia treatment market based on myopia treatment type, presbyopia treatment type, and region:
    Myopia Treatment Type Outlook (Revenue, USD Million, 2015 - 2026)